Dechra Pharmaceuticals Stock

DPH

GB0009633180

Market Closed - London S.E. 10:30:00 16/01/2024 +03			5-day change	1st Jan Change
3,866.00 ^GBX	-.--%		-.--%	-

08-17	Dechra Pharmaceuticals PLC Announces Appointment of Justine Conway as Chief Corporate Strategy and Business Development Officer	CI
06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI

Valuation: Dechra Pharmaceuticals

Market Cap	4.4B 5.84B 5.13B 4.86B 8.27B 560B 8.32B 58.13B 22.45B 286B 21.92B 21.44B 919B	P/E 2022	64.8x	P/E 2023	-150x
Enterprise Value	4.83B 6.41B 5.64B 5.33B 9.08B 615B 9.13B 63.81B 24.64B 314B 24.06B 23.54B 1,009B	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news: Dechra Pharmaceuticals

08-17	Dechra Pharmaceuticals PLC Announces Appointment of Justine Conway as Chief Corporate Strategy and Business Development Officer	CI
06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
03-31	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
03-11	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
03-11	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
13/10/25	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
13/10/25	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
03/09/25	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
18/08/25	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
17/06/25	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
05/05/25	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
05/05/25	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI

More news

Analysts' recommendations: Dechra Pharmaceuticals

27/06/23	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
27/06/23	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
27/06/23	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
07/03/23	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
12/01/23	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: Dechra Pharmaceuticals

27/12/23	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
30/10/23	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
17/10/23	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
17/10/23	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
07/09/23	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: Dechra Pharmaceuticals

12/01/24	BOLETÍN MATINAL : 12 de enero de 2024
13/12/23	Pharma und Gesundheit: weitere Konsolidierung
12/12/23	Farma en gezondheid: consolidatie gaat door
11/12/23	Farmaceutica e salute: continua il consolidamento
11/12/23	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: Dechra Pharmaceuticals

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	10/06/2024
Paul Sandland DFI	Director of Finance/CFO	46	03/04/2019
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	30/10/2019
Lawson Macartney BRD	Director/Board Member	68	01/12/2016
Lisa Bright BRD	Director/Board Member	59	01/02/2019

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

3 years	3,680	3,868
5 years	2,473.32	5,405
10 years	1,225	5,525

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/15/24 A	Ian Page	Free	Chief Executive Officer	3,580	0.0031%
1/15/24 A	Paul Sandland	Buy	Chief Financial Officer	227	0.0002%
1/15/24 A	Ian Page	Free	Chief Executive Officer	18,551	0.0163%

	2022	2023
Net sales	682M 904M 795M 752M 1.28B 86.76B 1.29B 9B 3.48B 44.27B 3.39B 3.32B 142B	762M 1.01B 888M 840M 1.43B 96.9B 1.44B 10.05B 3.88B 49.45B 3.79B 3.71B 159B
Net income	58.2M 77.15M 67.86M 64.17M 109M 7.41B 110M 768M 297M 3.78B 290M 283M 12.14B	-27.9M -36.99M -32.53M -30.76M -52.4M -3.55B -52.7M -368M -142M -1.81B -139M -136M -5.82B
Net Debt	208M 276M 243M 230M 391M 26.49B 393M 2.75B 1.06B 13.52B 1.04B 1.01B 43.44B	430M 570M 501M 474M 808M 54.73B 812M 5.68B 2.19B 27.93B 2.14B 2.09B 89.75B

Dechra Pharmaceuticals Stock

Stocks

DPH

GB0009633180

Valuation: Dechra Pharmaceuticals

Latest news: Dechra Pharmaceuticals

Analysts' recommendations: Dechra Pharmaceuticals

Press Releases: Dechra Pharmaceuticals

News in other languages: Dechra Pharmaceuticals

Price Extremes

Managers and Directors: Dechra Pharmaceuticals

Latest insider transactions

Financials

Company Profile